TABLE 6.
MDR phenotypea | No. of MDR isolates/period
|
Total no. of isolates | Serogroup/type (%) | ||
---|---|---|---|---|---|
1994-1998 | 1999-2001 | 2002-2004 | |||
PEN TET ERY CLI | 1 | 9 | 22 | 32 | 19 (31.3), 14 (25.0), 6 (15.6), 15 (15.6), 24 (6.3), 17 (3.1), 23 (3.1) |
PEN ERY SXT | 2 | 1 | 7 | 10 | 14 (90.0), 1 (10.0) |
PEN TET ERY | 9 | 9 | 19 (100) | ||
TET ERY CLI SXT | 2 | 5 | 1 | 8 | 6 (75.0), 14 (35.0) |
TET ERY CLI CHL SXT | 2 | 2 | 3 | 7 | 6 (71.4), 19 (28.6) |
PEN TET ERY CLI SXT | 1 | 2 | 4 | 7 | 6 (57.1), 9 (28.6), 19 (14.3) |
PEN TET ERY CLI CHL SXT | 2 | 4 | 6 | 23 (50.0), 6 (16.7), 14 (16.7), 19 (16.7) | |
PEN TET CHL SXT | 1 | 4 | 5 | 23 (80.0), 19 (20.0) | |
TET ERY CLI CHL | 3 | 3 | 19 (66.7), 6 (33.3) | ||
PEN TET CHL CTX CRO SXT | 2 | 1 | 3 | 23 (66.7), 19 (33.3) | |
ERY CLI CHL SXT | 2 | 2 | 6 (100) | ||
PEN ERY CLI SXT | 1 | 1 | 2 | 14 (50.0), 15 (50.0) | |
PEN TET ERY CLI CHL CTX CRO SXT | 1 | 1 | 2 | 6 (50.0), 23 (50.0) | |
TET CHL SXT | 1 | 1 | 6 (100) | ||
TET ERY CHL | 1 | 1 | 19 (100) | ||
TET ERY CHL SXT | 1 | 1 | 6 (100) | ||
PEN OFL CIP SXT | 1 | 1 | 11 (100) | ||
PEN ERY CTX CRO SXT | 1 | 1 | 14 (100) | ||
PEN ERY OFL CIP SXT | 1 | 1 | 14 (100) | ||
PEN TET SXT | 1 | 1 | 14 (100) | ||
PEN TET CHL CTX SXT | 1 | 1 | 23 (100) | ||
PEN TET ERY SXT | 1 | 1 | 19 (100) | ||
PEN TET ERY OFL CIP SXT | 1 | 1 | 14 (100) | ||
PEN TET ERY CHL SXT | 1 | 1 | 14 (100) | ||
PEN TET ERY CLI CTX SXT | 1 | 1 | 14 (100) | ||
PEN TET ERY CLI CTX CRO | 1 | 1 | 14 (100) | ||
PEN TET ERY CLI OFL CIP | 1 | 1 | 6 (100) | ||
PEN TET ERY CLI OFL CIP SXT | 1 | 1 | 14 (100) | ||
PEN TET ERY CLI CHL | 1 | 1 | 23 (100) | ||
Total | 17 | 30 | 65 | 112 |
PEN, penicillin; CRO, ceftriaxone; CTX, cefotaxime; TET, tetracycline; ERY, erythromycin; CLI, clindamycin; CHL, chloramphenicol; CIP, ciprofloxacin; OFX, ofloxacin; SXT, trimethoprim-sulfamethoxazole.